Literature DB >> 11786316

Neurotensin: an endogenous antipsychotic?

Becky Kinkead1, Charles B Nemeroff.   

Abstract

Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11786316     DOI： 10.1016/s1471-4892(01)00128-x

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  15 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  NDE1 and NDEL1 from genes to (mal)functions: parallel but distinct roles impacting on neurodevelopmental disorders and psychiatric illness.

Authors:  Nicholas J Bradshaw; Mirian A F Hayashi
Journal:  Cell Mol Life Sci       Date:  2016-10-14       Impact factor: 9.261

4.  Activation of central neurotensin receptors reinstates cocaine seeking in the rat: modulation by a D1/D5, but not D2/D3, receptor antagonist.

Authors:  Vanessa Lopak; Suzanne Erb
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

Review 6.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

7.  Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.

Authors:  Klara Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

8.  Sensorimotor gating in neurotensin-1 receptor null mice.

Authors:  D Feifel; Z Pang; P D Shilling; G Melendez; R Schreiber; D Button
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

9.  Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist.

Authors:  P D Shilling; G Melendez; K Priebe; E Richelson; D Feifel
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.